Skip to main content
OpenTrials
Completed

NCT Number: NCT04769596

Safety and Efficacy Study of the Neurent Medical NEUROMARK™ System in Subjects With Chronic Rhinitis

A randomized, sham-controlled, double-blind study of the NEUROMARKTM system as a treatment for chronic rhinitis

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alabama Allergy, Birmingham, Alabama, United States

Loading trial locations.

About this study

The MERIDIEN Study is a prospective, multi-center, double-blind, randomized (1:1), sham-controlled, cross-over study to evaluate the safety and efficacy of the NEUROMARK™ System in patients with Chronic Rhinitis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject provides written informed consent, including authorization to release health information.
  • Subject is 18 years of age or older at the time of consent.
  • Subject has provided a negative pregnancy test (if Subject is a woman of childbearing potential (WOCBP).
  • Subject WOCBP must be practicing and willing to continue an effective method of birth control during the course of the study.
  • Subjects stated willingness to comply with all study procedures, post- treatment care and availability for the duration of the study follow up of 1 year.
  • Subject tests negative for active COVID-19 at the start of study screening and continues to be free from COVID-19 symptoms until the time of enrollment/treatment.
  • Subject understands and agrees to follow local COVID-19 restrictions (social distancing, face mask, etc.)

Exclusion criteria

  • Subject has an allergy or intolerance to anaesthetic agent or other study-required materials.
  • Subject is an active smoker or has been a smoker within the last 6 months (patient reported).
  • Any physical condition that in the Investigator's opinion would prevent adequate study participation or pose increased risk to the study Subject.
  • Subject is pregnant, nursing or plans to become pregnant during the study, or is a WOCBP, but is not willing to use an effective method of birth control.
  • Patient is enrolled in an investigational drug or device study or has participated in such a study within the last 30 days prior to screening that in the opinion of the Investigator would interfere with the study results
  • Patient presents with any condition or situation which, in the Investigator's opinion, puts the Subject at risk, could confound the study results, or may interfere significantly with the Subject's participation in the study.

Treatment and study plan

NEUROMARK™ System

Device

The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.

Sham device

Device

A Sham device will be used in the nasal cavity

Primary outcomes

  1. Frequency of Serious Adverse Events (SAEs) directly attributable to the device

    Time frame: 1 month

    Safety

Sponsors and collaborators

Lead sponsor

Neurent Medical

Industry

Registry information

Official study title

Safety and Efficacy Study of the Neurent Medical NEUROMARK System in Subjects With Chronic Rhinitis A Double-blind, Sham Controlled Study

Acronym: MERIDIEN

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Feb 24, 2021
Registry last updated
Jul 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.